U.S. Uterine Fibroid Market Information By Type (Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and others), By Diagnosis (Medical Resonance Imaging (MRI) scanners, Computed Tomography (CT), Ultrasounds and others) and Treatment (Uterine Fibroid Embolization, Magnetic Resonance Guided Focused Ultrasound, Myolysis, Endometrial Ablation, Hysterectomy and Myomectomy) - Forecast to 2027
Overview:
Uterine fibroids can be classified as noncancerous growths of the uterus that can happen during childbearing years. The disease is also known as leiomyomas or myomas. The disease is not known to be cancerous, and its growth has rarely caused cancer. Fibroids, in this disease, look like seedlings in the beginning but then they turn into bulky masses that have the potential to distort and make uterus grow big. It is quite challenging to identify these fibroids as they can be undetectable. Such expansion of the uterus can touch the rib cage, and it can be sensed in the rapidly growing weight.
Symptoms of this disease are so benign that these fibroids often go unnoticed, however, this can be detected while undergoing pelvic exam or prenatal ultrasound. The US market for uterine fibroid is expected to gain substantial boost due to the growing awareness and high investment capacity, along with superior medical facilities. The hike in investment for the healthcare sector and better investment for research & development can inspire the global uterine fibroids market further.
Request Free Sample Copy at: https://www.marketresearchfuture.com/sample_request/2394
Segmentation:
The U.S. Uterine Fibroid Market can be segmented by type, diagnosis, and treatment. Such a segmentation relies heavily on factorial analyses that bring out insights, which can be used in the future for a better market understanding.
By type, the U.S. Uterine Fibroid Market can be studied as Submucosal Fibroids, Intramural Fibroids, Subserosal Fibroids, and others. These three segments are witnessing a substantial growth due to various reasons owing to which the market is expanding accordingly.
By diagnosis, the U.S. Uterine Fibroid market can be segmented into Computed tomography (CT), Medical Resonance Imaging (MRI) scanners, Ultrasounds, and others. Better technological integration is expected to provide high traction to the global market.
Based on the treatment, the U.S. Uterine Fibroid market includes Magnetic Resonance Guided Focused Ultrasound, Uterine Fibroid Embolization, Endometrial Ablation, Myolysis, Hysterectomy, and Myomectomy.
Regional Analysis:
A region-specific study of the U.S. Uterine Fibroid market covers mainly diverse states like Alabama, California, Arizona, Illinois, Massachusetts, Michigan, Nebraska, and others. The market in the region is finding moderate growth due to a high level of awareness, which influences women to have various preventive measures and timely treatment. The regional market is getting substantial backing from various market players who are getting involved in an intense competition to facilitate the growth of the market in the region. These players are launching strategic move to meet the growing demand for the market. The market is getting covered mostly by treatment with drug and surgery, however only surgery segment is also gaining prominence. However, the market may find a scope to rise by 18.96% CAGR during the forecast period from the pharmacotherapy segment. Some of the medicines now available in the market have received positive results from the clinical trial, which is why this segment is expected to gain more traction in the market in the coming years.
Competitive Landscape:
The U.S. market for the uterine fibroid has several companies participating as they have realized the vast potential of the market. The growing number of cases are demanding for better medication or treatment procedures, which have led these companies into devising various plans that can solidify their market position and assist in having growth for the market as a whole. MRFR profiled a few to have a better grasp over the market. These companies are AstraZeneca (England), Cook Medical Inc. (US), Boston Scientific Corporation (US), GE Healthcare (U.K.), AbbVie Inc. (U.S.), Hologic (U.S.), and others.
In September 2019, Abbvie filed for approval for their product Orilissa, a medicine for uterine fibroid. The company is banking on to gain from first-mover’s advantage. Myovant is also planning to launch Relugolix.
Browse Detailed TOC with COVID-19 Impact Analysis at: https://www.marketresearchfuture.com/reports/uterine-fibroid-market-2394
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.
Contact:
Akash Anand
Market Research Future
+1 646 845 9312
Email: [email protected]
Also termed as myomas or leiomyoma, uterine fibroids are non-cancerous growth which causes symptoms like pain in the pelvis and lower back, heavy bleeding during or between the menstrual cycle, and increased menstrual cramps along with the enlargement of the abdomen.Market Research Future (MRFR) speculates that the “U.S.
Uterine Fibroid Market Is Likely To Garner USD 39,993.2 Million, Grabbing a CAGR Of 3.24% During The Forecast Period (2016-2022)”.
Uterine Fibroid Market: Segmental AnalysisThe U.S. uterine fibroid market has been segmented on the basis of type, diagnosis, and treatment.By mode of type, the U.S. uterine fibroid market has been segmented into intramural fibroids, subserosal fibroids, submucosal fibroids, and others.By mode of diagnosis, the U.S. uterine fibroid market has been segmented into computed tomography (CT), medical resonance imaging (MRI) scanners, ultrasounds, and others.By mode of treatment, the U.S. uterine fibroid market has been segmented into magnetic resonance-guided focused ultrasound, uterine fibroid embolization, endometrial ablation, myolysis, hysterectomy, and myomectomy.
These surgeries being minimally invasive, reduces the chances of infection after surgery, shorter hospital stays, and minimal recovery time.
These advantages of hysterectomy and myomectomy are likely to contribute to the segment’s growth.Market Potential and PitfallsUterine fibroids are spreading over the entire U.S. at a rapid pace mainly due to the increased prevalence of uterine fibroids in the African-American race.
Several treatment options available such as pharmacotherapy, self-help techniques, invasive surgical procedures, and uterine artery embolization are propelling the market growth in the U.S.The introduction of minimally invasive surgeries such as myomectomy and hysterectomy for treating the excruciating pain of uterine fibroids is expected to encourage the market growth.
Uterine Fibroid Market Information By Type (Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and others), By Diagnosis (Medical Resonance Imaging (MRI) scanners, Computed Tomography (CT), Ultrasounds and others) and Treatment (Uterine Fibroid Embolization, Magnetic Resonance Guided Focused Ultrasound, Myolysis, Endometrial Ablation, Hysterectomy and Myomectomy) - Forecast to 2027Market ScenarioMarket Research Future (MRFR) speculates that the U.S. uterine fibroid market is likely to garner USD 39,993.2 million, grabbing a CAGR of 3.24% during the forecast period (2016-2022).
Also termed as myomas or leiomyoma, uterine fibroids are non-cancerous growth which causes symptoms like pain in the pelvis and lower back, heavy bleeding during or between the menstrual cycle, and increased menstrual cramps along with the enlargement of the abdomen.Market Potential and PitfallsUterine fibroids are spreading over the entire U.S. at a rapid pace mainly due to the increased prevalence of uterine fibroids in the African-American race.
The U.S. uterine fibroid market is anticipated to touch high growth figures in the long run mainly due to the surging prevalence of uterine fibroids and the rising number of hysterectomy surgeries every year.
Several treatment options available such as pharmacotherapy, self-help techniques, invasive surgical procedures, and uterine artery embolization are propelling the market growth in the U.S.The introduction of minimally invasive surgeries such as myomectomy and hysterectomy for treating the excruciating pain of uterine fibroids is expected to encourage the market growth.
Such surgeries have reduced the chances of infection, reduced the hospital stay, and, lowered the recovery time, thereby contributing to the growth.
This has resulted in limited treatment options for uterine fibroids.
Market ScenarioMarket Research Future (MRFR) speculates that the U.S. uterine fibroid market is likely to garner USD 39,993.2 million, grabbing a CAGR of 3.24% during the forecast period (2016-2022).
Also termed as myomas or leiomyoma, uterine fibroids are non-cancerous growth which causes symptoms like pain in the pelvis and lower back, heavy bleeding during or between the menstrual cycle, and increased menstrual cramps along with the enlargement of the abdomen.Request Sample Copy:https://www.marketresearchfuture.com/sample_request/2394Symptoms of this disease are so benign that these fibroids often go unnoticed, however, this can be detected while undergoing pelvic exam or prenatal ultrasound.
The US market for uterine fibroid is expected to gain substantial boost due to the growing awareness and high investment capacity, along with superior medical facilities.
The hike in investment for the healthcare sector and better investment for research & development can inspire the global uterine fibroids market further.Segmentation:The U.S.
Such a segmentation relies heavily on factorial analyses that bring out insights, which can be used in the future for a better market understanding.By type, the Uterine Fibroid Market can be studied as Submucosal Fibroids, Intramural Fibroids, Subserosal Fibroids, and others.
Uterine Fibroid market includes Magnetic Resonance Guided Focused Ultrasound, Uterine Fibroid Embolization, Endometrial Ablation, Myolysis, Hysterectomy, and Myomectomy.Regional InsightsThe U.S. uterine fibroid market is expanding at a steady pace with a CAGR of 3.24% by the end of 2022.
